JP2007505875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505875A5 JP2007505875A5 JP2006526686A JP2006526686A JP2007505875A5 JP 2007505875 A5 JP2007505875 A5 JP 2007505875A5 JP 2006526686 A JP2006526686 A JP 2006526686A JP 2006526686 A JP2006526686 A JP 2006526686A JP 2007505875 A5 JP2007505875 A5 JP 2007505875A5
- Authority
- JP
- Japan
- Prior art keywords
- quinazoline
- chloro
- piperidin
- oxy
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003246 quinazolines Chemical class 0.000 claims 46
- -1 cyano, nitro, hydroxy, amino, carboxy, sulfamoyl Chemical group 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000524 functional group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000003282 alkyl amino group Chemical group 0.000 claims 9
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- SHSMZPYXZURMEE-UHFFFAOYSA-N 2-[4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C=12C=C(OC3CCN(CC(=O)N4CCN(C)CC4)CC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F SHSMZPYXZURMEE-UHFFFAOYSA-N 0.000 claims 2
- QRVGWOQDGHNNOJ-UHFFFAOYSA-N 2-[4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-1-piperazin-1-ylethanone Chemical compound C=12C=C(OC3CCN(CC(=O)N4CCNCC4)CC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F QRVGWOQDGHNNOJ-UHFFFAOYSA-N 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 claims 2
- 150000003335 secondary amines Chemical class 0.000 claims 2
- TUJMSLXGODIOSJ-UHFFFAOYSA-N 2-[4-[4-(3-chloro-2,4-difluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C=12C=C(OC3CCN(CC(=O)N4CCN(C)CC4)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1F TUJMSLXGODIOSJ-UHFFFAOYSA-N 0.000 claims 1
- OYVGKMHHOZESFV-UHFFFAOYSA-N 2-[4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-1-morpholin-4-ylethanone Chemical compound C=12C=C(OC3CCN(CC(=O)N4CCOCC4)CC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F OYVGKMHHOZESFV-UHFFFAOYSA-N 0.000 claims 1
- QJKLDSLAYNMJPH-UHFFFAOYSA-N 2-[4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-1-morpholin-4-ylethanone Chemical compound C=12C=C(OC3CCN(CC(=O)N4CCOCC4)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 QJKLDSLAYNMJPH-UHFFFAOYSA-N 0.000 claims 1
- YAMOXVHULRXADY-UHFFFAOYSA-N 2-[4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-1-pyrrolidin-1-ylethanone Chemical compound C=12C=C(OC3CCN(CC(=O)N4CCCC4)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YAMOXVHULRXADY-UHFFFAOYSA-N 0.000 claims 1
- DWKBIQXIOVLREL-UHFFFAOYSA-N 2-[4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-n,n-dimethylacetamide Chemical compound C=12C=C(OC3CCN(CC(=O)N(C)C)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 DWKBIQXIOVLREL-UHFFFAOYSA-N 0.000 claims 1
- UUHJZHSXOPNXJK-UHFFFAOYSA-N 2-[4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-n-methylacetamide Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=C(F)C(Cl)=C1 UUHJZHSXOPNXJK-UHFFFAOYSA-N 0.000 claims 1
- BPJGLRNTMKLTFV-UHFFFAOYSA-N 2-[4-[4-(3-chloro-4-fluoroanilino)quinazolin-6-yl]oxypiperidin-1-yl]-1-morpholin-4-ylethanone Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC=C2OC1CCN(CC(=O)N2CCOCC2)CC1 BPJGLRNTMKLTFV-UHFFFAOYSA-N 0.000 claims 1
- KFLQUVCHGBIZNL-UHFFFAOYSA-N 2-[4-[4-(3-chloro-4-fluoroanilino)quinazolin-6-yl]oxypiperidin-1-yl]-n,n-dimethylacetamide Chemical compound C1CN(CC(=O)N(C)C)CCC1OC1=CC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=C1 KFLQUVCHGBIZNL-UHFFFAOYSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- AJGCCHYJVIYICA-UHFFFAOYSA-N 3-[4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-1-morpholin-4-ylpropan-1-one Chemical compound C=12C=C(OC3CCN(CCC(=O)N4CCOCC4)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 AJGCCHYJVIYICA-UHFFFAOYSA-N 0.000 claims 1
- VDDLIDPTQSBAAT-UHFFFAOYSA-N 4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n-(2-pyrrolidin-1-ylethyl)piperidine-1-carboxamide Chemical compound C=12C=C(OC3CCN(CC3)C(=O)NCCN3CCCC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F VDDLIDPTQSBAAT-UHFFFAOYSA-N 0.000 claims 1
- LYTUHALVDRDFOK-UHFFFAOYSA-N 4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n-methylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F LYTUHALVDRDFOK-UHFFFAOYSA-N 0.000 claims 1
- WMBRKFRXBSLUHE-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n,n-diethylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)N(CC)CC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=C(F)C(Cl)=C1 WMBRKFRXBSLUHE-UHFFFAOYSA-N 0.000 claims 1
- IQGVKORQJHVGOB-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n,n-dimethylpiperidine-1-carboxamide Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 IQGVKORQJHVGOB-UHFFFAOYSA-N 0.000 claims 1
- MLCJKARGBIMLJM-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n-ethylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NCC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=C(F)C(Cl)=C1 MLCJKARGBIMLJM-UHFFFAOYSA-N 0.000 claims 1
- BDCBLXLWPRFFPU-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n-methylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=C(F)C(Cl)=C1 BDCBLXLWPRFFPU-UHFFFAOYSA-N 0.000 claims 1
- TYDXNUIFLUEDFR-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)quinazolin-6-yl]oxy-n,n-dimethylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)N(C)C)CCC1OC1=CC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=C1 TYDXNUIFLUEDFR-UHFFFAOYSA-N 0.000 claims 1
- OPXXBONXLXHZNU-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-1-morpholin-4-ylbutan-1-one Chemical compound C=12C=C(OC3CCN(CCCC(=O)N4CCOCC4)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 OPXXBONXLXHZNU-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- SNUHGTFGVZBUPD-UHFFFAOYSA-N [4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F SNUHGTFGVZBUPD-UHFFFAOYSA-N 0.000 claims 1
- BHKSATWJMGPDRI-UHFFFAOYSA-N [4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-pyrrolidin-1-ylmethanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCCC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F BHKSATWJMGPDRI-UHFFFAOYSA-N 0.000 claims 1
- HGQSWGUVSJUFJD-UHFFFAOYSA-N [4-[4-(3-chloro-4-fluoroanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxypiperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCOCC3)C(OCCOC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 HGQSWGUVSJUFJD-UHFFFAOYSA-N 0.000 claims 1
- IWYSVFZTNXLAOF-UHFFFAOYSA-N [4-[4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl]oxypiperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCOCC3)C(OCC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 IWYSVFZTNXLAOF-UHFFFAOYSA-N 0.000 claims 1
- XFVIYGALQWSYAD-UHFFFAOYSA-N [4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCN(C)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XFVIYGALQWSYAD-UHFFFAOYSA-N 0.000 claims 1
- SGPQZLAIXLGTBH-UHFFFAOYSA-N [4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 SGPQZLAIXLGTBH-UHFFFAOYSA-N 0.000 claims 1
- GCFQYHBVQUQWIX-UHFFFAOYSA-N [4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-piperidin-1-ylmethanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 GCFQYHBVQUQWIX-UHFFFAOYSA-N 0.000 claims 1
- AKGOXFWKPNRRRD-UHFFFAOYSA-N [4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-pyrrolidin-1-ylmethanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 AKGOXFWKPNRRRD-UHFFFAOYSA-N 0.000 claims 1
- OTYKNBPRZBCEBA-UHFFFAOYSA-N [4-[4-(3-chloro-4-fluoroanilino)quinazolin-6-yl]oxypiperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC=C2OC1CCN(C(=O)N2CCOCC2)CC1 OTYKNBPRZBCEBA-UHFFFAOYSA-N 0.000 claims 1
- COUMVWRRFZOSEJ-UHFFFAOYSA-N [4-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 COUMVWRRFZOSEJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 125000005133 alkynyloxy group Chemical group 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 C*C(N(*)*)=O Chemical compound C*C(N(*)*)=O 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03292309 | 2003-09-19 | ||
| EP04291248 | 2004-05-14 | ||
| PCT/GB2004/003937 WO2005028469A1 (en) | 2003-09-19 | 2004-09-15 | Quinazoline derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007240846A Division JP2008037874A (ja) | 2003-09-19 | 2007-09-18 | キナゾリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505875A JP2007505875A (ja) | 2007-03-15 |
| JP2007505875A5 true JP2007505875A5 (OSRAM) | 2007-07-05 |
| JP4036885B2 JP4036885B2 (ja) | 2008-01-23 |
Family
ID=34379392
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526686A Expired - Fee Related JP4036885B2 (ja) | 2003-09-19 | 2004-09-15 | キナゾリン誘導体 |
| JP2007240846A Pending JP2008037874A (ja) | 2003-09-19 | 2007-09-18 | キナゾリン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007240846A Pending JP2008037874A (ja) | 2003-09-19 | 2007-09-18 | キナゾリン誘導体 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8318752B2 (OSRAM) |
| EP (1) | EP1667992B1 (OSRAM) |
| JP (2) | JP4036885B2 (OSRAM) |
| KR (1) | KR101262442B1 (OSRAM) |
| CN (1) | CN1882569B (OSRAM) |
| AR (1) | AR045762A1 (OSRAM) |
| AT (1) | ATE352550T1 (OSRAM) |
| AU (1) | AU2004274227B2 (OSRAM) |
| BR (1) | BRPI0414532B1 (OSRAM) |
| CA (1) | CA2538752C (OSRAM) |
| CO (1) | CO5680435A2 (OSRAM) |
| CY (1) | CY1106405T1 (OSRAM) |
| DE (1) | DE602004004553T2 (OSRAM) |
| DK (1) | DK1667992T3 (OSRAM) |
| ES (1) | ES2279441T3 (OSRAM) |
| HR (1) | HRP20070113T3 (OSRAM) |
| IL (1) | IL174284A (OSRAM) |
| IS (1) | IS2545B (OSRAM) |
| MX (1) | MXPA06003113A (OSRAM) |
| MY (1) | MY138851A (OSRAM) |
| NO (1) | NO333904B1 (OSRAM) |
| NZ (1) | NZ545913A (OSRAM) |
| PL (1) | PL1667992T3 (OSRAM) |
| PT (1) | PT1667992E (OSRAM) |
| RU (1) | RU2370494C2 (OSRAM) |
| SA (1) | SA04250296B1 (OSRAM) |
| SI (1) | SI1667992T1 (OSRAM) |
| TW (1) | TWI342879B (OSRAM) |
| UA (1) | UA83252C2 (OSRAM) |
| UY (1) | UY28522A1 (OSRAM) |
| WO (1) | WO2005028469A1 (OSRAM) |
| ZA (1) | ZA200602264B (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| DK1667991T3 (da) | 2003-09-16 | 2008-08-18 | Astrazeneca Ab | Quinazolinderivater som tyrosinkinaseinhibitorer |
| EP1670782B1 (en) * | 2003-09-19 | 2007-02-14 | AstraZeneca AB | Quinazoline derivatives |
| DE602004004553T2 (de) | 2003-09-19 | 2007-10-25 | Astrazeneca Ab | Chinazolinderivate |
| EP1670786A1 (en) * | 2003-09-25 | 2006-06-21 | Astrazeneca AB | Quinazoline derivatives |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
| DE602005026865D1 (de) * | 2004-12-14 | 2011-04-21 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| ATE521603T1 (de) * | 2005-02-26 | 2011-09-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| CN101175733A (zh) * | 2005-05-12 | 2008-05-07 | 黄文林 | 一种酪氨酸激酶抑制剂、其制备方法及作为抗肿瘤药物的应用 |
| WO2007029251A2 (en) * | 2005-09-06 | 2007-03-15 | T.K. Signal Ltd. | Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase |
| KR20080077009A (ko) * | 2005-12-12 | 2008-08-20 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약제,이의 용도 및 이의 제조방법 |
| EP1921070A1 (de) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
| EP2245026B1 (de) | 2008-02-07 | 2012-08-01 | Boehringer Ingelheim International GmbH | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2009138780A2 (en) * | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Therapeutic treatment - 355 |
| WO2009138779A1 (en) * | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline |
| AU2009247782C1 (en) * | 2008-05-13 | 2013-09-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline |
| CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| WO2010061208A2 (en) * | 2008-11-03 | 2010-06-03 | Astrazeneca Ab | Therapeutic treatment 555 |
| AU2010240717A1 (en) * | 2009-04-23 | 2011-10-27 | Astrazeneca Ab | Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-[1- (N-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline |
| CN102060875B (zh) * | 2009-11-18 | 2014-03-12 | 天津药物研究院 | 喹唑啉衍生物、制备方法和用途 |
| UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| CN103012368A (zh) * | 2011-09-22 | 2013-04-03 | 北大方正集团有限公司 | 喹啉衍生物 |
| CN103012367A (zh) * | 2011-09-22 | 2013-04-03 | 北大方正集团有限公司 | 一种喹啉衍生物 |
| TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
| KR20140096571A (ko) * | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
| MY186126A (en) | 2013-03-06 | 2021-06-24 | Astrazeneca Ab | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
| CN104513229A (zh) * | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| RU2720810C2 (ru) | 2015-03-20 | 2020-05-13 | Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. | Соли производного хиназолина и способ их получения |
| WO2017122205A1 (en) | 2016-01-13 | 2017-07-20 | Hadasit Medical Research Services And Development Ltd. | Radiolabeled erlotinib analogs and uses thereof |
| WO2021090245A1 (en) | 2019-11-06 | 2021-05-14 | Yuhan Corporation | Pyrrolidine and piperidine compounds |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985749A (en) * | 1975-12-22 | 1976-10-12 | Eastman Kodak Company | Process for preparation of 4-aminoquinazoline |
| JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| US4332420A (en) | 1980-01-11 | 1982-06-01 | Coski William D | Reciprocably supported dual drive member and features thereof |
| GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
| KR910006138B1 (ko) | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
| CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| JPH0436885A (ja) * | 1990-05-31 | 1992-02-06 | Sharp Corp | 光学式文字読取装置 |
| US5252586A (en) * | 1990-09-28 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents |
| DE4105503A1 (de) | 1991-02-19 | 1992-08-20 | Jenapharm Gmbh | Ausgangsverbindungen zur herstellung von calcitriol sowie dessen abkoemmlingen, verfahren zur herstellung dieser ausgangsverbindungen sowie zwischenprodukte fuer dieses verfahren |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| DK0584222T3 (da) | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| US5187168A (en) | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| HUT74870A (en) | 1993-05-26 | 1997-02-28 | Syntex Inc | Process for producing 1-phenylalkanone 5-ht4 receptor ligands and pharmaceutical compositions containing them |
| US5395846A (en) | 1993-06-25 | 1995-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| TW321649B (OSRAM) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| AU1721697A (en) * | 1996-01-31 | 1997-08-22 | Gist-Brocades B.V. | Use of compositions comprising stabilized biologically effective compounds |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9626589D0 (en) * | 1996-12-20 | 1997-02-05 | Prolifix Ltd | Peptides |
| US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
| JP4245682B2 (ja) | 1997-12-25 | 2009-03-25 | 協和発酵キリン株式会社 | キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤 |
| US6384223B1 (en) * | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| CZ20013079A3 (cs) * | 1999-02-27 | 2001-11-14 | Boehringer Ingelheim Pharma Kg | Deriváty 4-aminochinazolinu a chinolinu |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2000068203A1 (en) * | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| US6126917A (en) * | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
| SK287010B6 (sk) * | 1999-06-21 | 2009-09-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie |
| MX226123B (es) | 1999-09-17 | 2005-02-07 | Millennium Pharm Inc | Benzamidas e inhibidores del factor xa relacionadas. |
| WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| GB9925958D0 (en) | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| WO2001076630A1 (en) * | 2000-04-06 | 2001-10-18 | Kyowa Hakko Kogyo Co., Ltd. | Diagnostics and remedies for rheumatoid arthritis |
| US20040110743A1 (en) | 2000-05-19 | 2004-06-10 | Masaomi Miyamato | -Secretase inhibitors |
| GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
| DE10042061A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10042060A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6656946B2 (en) * | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| DE10042059A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10042062A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung |
| US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6740651B2 (en) * | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6653305B2 (en) * | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| AU8690901A (en) | 2000-09-01 | 2002-03-13 | Fmc Corp | Disubstituted benzenes as insecticides |
| BR0113625A (pt) | 2000-09-08 | 2003-07-22 | Pharmacia Italia Spa | Exemestano como agente de quimioprevenção |
| AU2002213467A1 (en) | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Modulation of ccr4 function |
| US20030158196A1 (en) * | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| US20040034026A1 (en) * | 2000-11-22 | 2004-02-19 | Wood Jeannette M | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| EP1350793A1 (en) * | 2000-12-11 | 2003-10-08 | Takeda Chemical Industries, Ltd. | Medicinal compositions having improved absorbability |
| US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| ATE475652T1 (de) | 2001-02-21 | 2010-08-15 | Mitsubishi Tanabe Pharma Corp | Chinazolinderivate |
| US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| EP1396488A1 (en) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| EP1578722A4 (en) | 2001-10-12 | 2006-09-06 | Irm Llc | KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF |
| JP2003246780A (ja) | 2001-12-17 | 2003-09-02 | Eisai Co Ltd | 含窒素芳香環化合物の製造方法 |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| EP1481971B1 (en) * | 2002-02-06 | 2011-11-16 | Ube Industries, Ltd. | Process for producing 4-aminoquinazoline compound |
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| PL371188A1 (en) * | 2002-03-30 | 2005-06-13 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| US20040044014A1 (en) * | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| WO2003099276A1 (en) | 2002-05-10 | 2003-12-04 | Bristol-Myers Squibb Company | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
| WO2003097086A2 (en) | 2002-05-15 | 2003-11-27 | Technische Universität München | Egf receptor antagonists in the treatment of gastric cancer |
| AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| EP1510221A4 (en) * | 2002-06-03 | 2009-04-29 | Mitsubishi Tanabe Pharma Corp | MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR |
| CA2491191C (en) | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
| AU2003256783A1 (en) | 2002-07-25 | 2004-02-16 | Scios, Inc. | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS |
| AU2003247141A1 (en) | 2002-08-01 | 2004-02-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases |
| CN1688549A (zh) * | 2002-08-23 | 2005-10-26 | 麒麟麦酒株式会社 | 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物 |
| WO2004060400A1 (ja) * | 2003-01-06 | 2004-07-22 | Mitsubishi Pharma Corp | 上皮成長因子受容体を分子標的とする抗精神病薬 |
| DE10300098A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Ag | Kupfer-Carben-Komplexe und ihre Verwendung |
| DE10300097A1 (de) * | 2003-01-07 | 2004-07-22 | Bayer Ag | Kupfer-Komplexe und ihre Verwendung |
| WO2004072038A1 (en) | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| JP2007517767A (ja) | 2003-03-11 | 2007-07-05 | ダナ ファーバー キャンサー インスティテュート | ウイルスの病原性の阻害方法 |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| JP2007500248A (ja) | 2003-06-09 | 2007-01-11 | ワクサル，サムエル | 細胞外アンタゴニストおよび細胞内アンタゴニストによる受容体チロシンキナーゼの抑制方法 |
| GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| KR20060054388A (ko) * | 2003-07-29 | 2006-05-22 | 아스트라제네카 아베 | 티로신 키나아제 억제제로서의 피페리딜-퀴나졸린 유도체 |
| SG135193A1 (en) | 2003-08-18 | 2007-09-28 | Pfizer Prod Inc | Dosing schedule for erbb2 anticancer agents |
| DE602004004553T2 (de) | 2003-09-19 | 2007-10-25 | Astrazeneca Ab | Chinazolinderivate |
| EP1670782B1 (en) * | 2003-09-19 | 2007-02-14 | AstraZeneca AB | Quinazoline derivatives |
| EP1670786A1 (en) * | 2003-09-25 | 2006-06-21 | Astrazeneca AB | Quinazoline derivatives |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| US20050096332A1 (en) * | 2003-10-30 | 2005-05-05 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| CN105106199A (zh) | 2006-12-14 | 2015-12-02 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
-
2004
- 2004-09-15 DE DE602004004553T patent/DE602004004553T2/de not_active Expired - Lifetime
- 2004-09-15 ES ES04768483T patent/ES2279441T3/es not_active Expired - Lifetime
- 2004-09-15 EP EP04768483A patent/EP1667992B1/en not_active Expired - Lifetime
- 2004-09-15 NZ NZ545913A patent/NZ545913A/en not_active IP Right Cessation
- 2004-09-15 AU AU2004274227A patent/AU2004274227B2/en not_active Ceased
- 2004-09-15 CN CN2004800339015A patent/CN1882569B/zh not_active Expired - Fee Related
- 2004-09-15 BR BRPI0414532-1A patent/BRPI0414532B1/pt not_active IP Right Cessation
- 2004-09-15 US US10/571,991 patent/US8318752B2/en not_active Expired - Fee Related
- 2004-09-15 PT PT04768483T patent/PT1667992E/pt unknown
- 2004-09-15 WO PCT/GB2004/003937 patent/WO2005028469A1/en not_active Ceased
- 2004-09-15 UA UAA200604367A patent/UA83252C2/uk unknown
- 2004-09-15 CA CA2538752A patent/CA2538752C/en not_active Expired - Fee Related
- 2004-09-15 JP JP2006526686A patent/JP4036885B2/ja not_active Expired - Fee Related
- 2004-09-15 SI SI200430224T patent/SI1667992T1/sl unknown
- 2004-09-15 RU RU2006112845/04A patent/RU2370494C2/ru not_active IP Right Cessation
- 2004-09-15 MX MXPA06003113A patent/MXPA06003113A/es active IP Right Grant
- 2004-09-15 HR HR20070113T patent/HRP20070113T3/xx unknown
- 2004-09-15 PL PL04768483T patent/PL1667992T3/pl unknown
- 2004-09-15 DK DK04768483T patent/DK1667992T3/da active
- 2004-09-15 AT AT04768483T patent/ATE352550T1/de active
- 2004-09-16 MY MYPI20043767A patent/MY138851A/en unknown
- 2004-09-17 TW TW093128316A patent/TWI342879B/zh not_active IP Right Cessation
- 2004-09-17 AR ARP040103357A patent/AR045762A1/es not_active Application Discontinuation
- 2004-09-17 UY UY28522A patent/UY28522A1/es not_active Application Discontinuation
- 2004-09-18 SA SA4250296A patent/SA04250296B1/ar unknown
-
2006
- 2006-03-13 IL IL174284A patent/IL174284A/en active IP Right Grant
- 2006-03-17 ZA ZA2006/02264A patent/ZA200602264B/en unknown
- 2006-03-23 NO NO20061327A patent/NO333904B1/no not_active IP Right Cessation
- 2006-04-12 IS IS8412A patent/IS2545B/is unknown
- 2006-04-17 CO CO06036294A patent/CO5680435A2/es active IP Right Grant
- 2006-04-19 KR KR1020067007482A patent/KR101262442B1/ko not_active Expired - Fee Related
-
2007
- 2007-03-22 CY CY20071100399T patent/CY1106405T1/el unknown
- 2007-09-18 JP JP2007240846A patent/JP2008037874A/ja active Pending
-
2012
- 2012-09-10 US US13/607,999 patent/US20120329795A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505875A5 (OSRAM) | ||
| CA2538752A1 (en) | Quinazoline derivatives | |
| JP2007505878A5 (OSRAM) | ||
| CN1190197C (zh) | 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途 | |
| JP2021011495A5 (OSRAM) | ||
| CN101039673B (zh) | 用于治疗涉及细胞增殖的疾病的组合 | |
| JP6527534B2 (ja) | ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物 | |
| CN1100540C (zh) | 具有选择性抑制her－2自磷酸化性质的蛋白质酪氨酸激酶芳基和杂芳基喹唑啉化合物 | |
| TWI337866B (en) | Chemical compounds | |
| CN112654612A (zh) | 作为抗肿瘤剂的喹唑啉衍生物 | |
| JP2012520867A5 (OSRAM) | ||
| JP2015500212A5 (OSRAM) | ||
| JP2020521740A5 (OSRAM) | ||
| CN1298328C (zh) | 包括应用zd6474和紫杉烷的联合疗法 | |
| JP2017525757A5 (OSRAM) | ||
| JPWO2020086739A5 (OSRAM) | ||
| JP2007517807A5 (OSRAM) | ||
| Liu et al. | Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1, 2, 4-triazolone moiety as c-Met kinase inhibitors | |
| JP2010522194A5 (OSRAM) | ||
| JP2016525509A5 (OSRAM) | ||
| JP2010516692A (ja) | 化学療法剤に対し抵抗性を有する癌の処置 | |
| RU2007134396A (ru) | Химические соединения | |
| JP2009536620A5 (OSRAM) | ||
| JP2008515959A5 (OSRAM) | ||
| JP2005529092A5 (OSRAM) |